Pharmaceutical

GSK’s Omjjara gains approval in Japan for myelofibrosis treatment

GSK has received approval from the Japan's Ministry of Health, Labour and Welfare (MHLW) for Omjjara to treat patients with myelofibrosis.

Jun 26, 2024 - 04:00
GSK’s Omjjara gains approval in Japan for myelofibrosis treatment
GSK has received approval from the Japan's Ministry of Health, Labour and Welfare (MHLW) for Omjjara to treat patients with myelofibrosis.
Read the original article

Tags:

Previous Article

Novavax seeks EMA approval for updated JN.1 Covid-19 vaccine

Next Article

Novo Nordisk invests $4.1bn in manufacturing facility in NC

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

ALG.APV-527 by Alligator Bioscience for Solid Tumor: Likelihood of Approval

ALG.APV-527 by Alligator Bioscience for Solid Tumor: Li...

Nov 2, 2023

Erasca trims workforce and pipeline to focus on KRAS and molecular glues

Erasca trims workforce and pipeline to focus on KRAS an...

May 19, 2024

F. Hoffmann-La Roche sees highest patent filings and grants during August in Q3 2023

F. Hoffmann-La Roche sees highest patent filings and gr...

Nov 24, 2023